2024
Perioperative Modified FOLFIRINOX for Resectable Pancreatic Cancer
Cecchini M, Salem R, Robert M, Czerniak S, Blaha O, Zelterman D, Rajaei M, Townsend J, Cai G, Chowdhury S, Yugawa D, Tseng R, Arbelaez C, Jiao J, Shroyer K, Thumar J, Kortmansky J, Zaheer W, Fischbach N, Persico J, Stein S, Khan S, Cha C, Billingsley K, Kunstman J, Johung K, Wiess C, Muzumdar M, Spickard E, Aushev V, Laliotis G, Jurdi A, Liu M, Escobar-Hoyos L, Lacy J. Perioperative Modified FOLFIRINOX for Resectable Pancreatic Cancer. JAMA Oncology 2024, 10: 1027-1035. PMID: 38900452, PMCID: PMC11190830, DOI: 10.1001/jamaoncol.2024.1575.Peer-Reviewed Original ResearchProgression-free survivalPancreatic ductal adenocarcinomaOverall survivalCtDNA levelsPhase 2 nonrandomized controlled trialAnalysis of circulating tumor DNAMedian progression-free survivalResectable pancreatic ductal adenocarcinomaControlled trialsAssess surgical candidacyBaseline ctDNA levelModified 5-fluorouracilResectable pancreatic cancerPancreatic protocol computed tomographyAssociated with recurrenceTumor molecular featuresAggressive malignant tumorKaplan-Meier estimatesRandomized clinical trialsStandard of careCtDNA-positivePreoperative cyclesNonrandomized controlled trialsUnresectable diseaseModified FOLFIRINOXArtificial intelligence–aided steatosis assessment in donor livers according to the Banff consensus recommendations
Jiao J, Tang H, Sun N, Zhang X. Artificial intelligence–aided steatosis assessment in donor livers according to the Banff consensus recommendations. American Journal Of Clinical Pathology 2024, 162: 401-407. PMID: 38716796, DOI: 10.1093/ajcp/aqae053.Peer-Reviewed Original ResearchBanff Working GroupLiver Allograft PathologyBiopsy specimensDonor liversAllograft pathologyAssociated with primary graft dysfunctionMacrovesicular steatosisPrimary graft dysfunctionManual quantificationSteatosis assessmentLiver biopsy specimensSevere macrovesicular steatosisAssessment of liver steatosisGraft dysfunctionPathological evaluationModerate steatosisEvaluate steatosisConsensus recommendationsLiver steatosisSteatosisBanffLiverPathologyAI modelsArtificial intelligenceGlycerol Kinase Deficiency with Increased Triglycerides and Weight Gain: Pseudo or Real?
Jiao J, Bernard P, Meeusen J, Militello L, El-Khoury J. Glycerol Kinase Deficiency with Increased Triglycerides and Weight Gain: Pseudo or Real? Clinical Chemistry 2024, 70: 703-706. PMID: 38692658, DOI: 10.1093/clinchem/hvae032.Peer-Reviewed Original Research
2023
Detection of Large-Droplet Macrovesicular Steatosis in Donor Livers Based on Segment-Anything Model
Tang H, Jiao J, Lin J, Zhang X, Sun N. Detection of Large-Droplet Macrovesicular Steatosis in Donor Livers Based on Segment-Anything Model. Laboratory Investigation 2023, 104: 100288. PMID: 37977550, DOI: 10.1016/j.labinv.2023.100288.Peer-Reviewed Original ResearchLiver diseaseMacrovesicular steatosisArtificial intelligence algorithmsArtificial intelligence modelsEnd-stage liver diseaseRule-based algorithmLiver histology analysisLiver transplant complicationsAcute liver failurePrimary hepatic malignancyLarge fat vacuolesIntelligence algorithmsDetection modelTransformer architectureIntelligence modelsTransplant complicationsLiver transplantationLiver failureLiver biopsyHepatic malignanciesFat vacuolesDonor organsEffective treatmentPrior knowledgeAlgorithmHeterogeneity in intrahepatic macrophage populations and druggable target expression in patients with steatotic liver disease-related fibrosis.
Saldarriaga OA, Wanninger TG, Arroyave E, Gosnell J, Krishnan S, Oneka M, Bao D, Millian DE, Kueht ML, Moghe A, Jiao J, Sanchez JI, Spratt H, Beretta L, Rao A, Burks JK, Stevenson HL. Heterogeneity in intrahepatic macrophage populations and druggable target expression in patients with steatotic liver disease-related fibrosis. JHEP Rep 2023, 6: 100958. PMID: 38162144, DOI: 10.1016/j.jhepr.2023.100958.Peer-Reviewed Original ResearchPostinfantile Giant Cell Hepatitis in Native and Allograft Livers: A Multi-Institutional Clinicopathologic Study of 70 Cases
Jiao J, Chezar K, Zhang X, Wang D, Cao W, Bindu C, Chen W, Neto A, Henn P, Riahi I, Wang H, Papke D, Zhao L, Xue Y, Liao X, Zhang X. Postinfantile Giant Cell Hepatitis in Native and Allograft Livers: A Multi-Institutional Clinicopathologic Study of 70 Cases. Modern Pathology 2023, 36: 100298. PMID: 37544363, DOI: 10.1016/j.modpat.2023.100298.Peer-Reviewed Original ResearchConceptsPostinfantile giant cell hepatitisAutoimmune liver diseaseGiant cell hepatitisAlkaline phosphatase levelsClinical outcomesPhosphatase levelsLiver diseaseMulti-institutional retrospective studyAssociated with better survivalAssociated with poor survivalClinicopathological characteristics of patientsAdverse prognostic factorAssociated with autoimmune liver diseasesGiant cellsVariable clinical outcomesFollow-up resultsCharacteristics of patientsDistribution of giant cellsOlder ageLiver disease etiologyPrognostic factorsAdvanced fibrosisBetter survivalClinicopathological characteristicsLiver allograftsHepatocellular Adenoma: Report of 2 Cases That Highlight the Relevance of Phenotype-Genotype Correlation in the Pediatric Population
Jiao J, Finberg K, Jain D, Morotti R. Hepatocellular Adenoma: Report of 2 Cases That Highlight the Relevance of Phenotype-Genotype Correlation in the Pediatric Population. Pediatric And Developmental Pathology 2023, 26: 394-403. PMID: 37334553, DOI: 10.1177/10935266231175426.Peer-Reviewed Case Reports and Technical NotesConceptsHepatocellular adenomaPediatric populationInflammatory HCASonic hedgehog hepatocellular adenomasYoung type 3Maturity-onset diabetesInflammatory hepatocellular adenomaΒ-catenin-activated hepatocellular adenomaAbernethy malformationPhenotype-genotype correlationClinical historyHCA subtypesH-HCACase 2Case 1Type 3Pathological informationB-HCASubtypesFamily surveillanceLimited studiesMalesCellular and Molecular Mechanisms of Liver Fibrosis in Patients with NAFLD.
Sanchez JI, Parra ER, Jiao J, Solis Soto LM, Ledesma DA, Saldarriaga OA, Stevenson HL, Beretta L. Cellular and Molecular Mechanisms of Liver Fibrosis in Patients with NAFLD. Cancers (Basel) 2023, 15 PMID: 37296834, DOI: 10.3390/cancers15112871.Peer-Reviewed Original ResearchApplication of the International System for Reporting Serous Fluid Cytopathology to pericardial fluid: Root cause analysis of indeterminate diagnoses, cytohistological correlation, and assessment of malignancy risk
Wang M, Sun T, Jiao J, Wang H. Application of the International System for Reporting Serous Fluid Cytopathology to pericardial fluid: Root cause analysis of indeterminate diagnoses, cytohistological correlation, and assessment of malignancy risk. Cancer Cytopathology 2023, 131: 433-441. PMID: 36973963, DOI: 10.1002/cncy.22696.Peer-Reviewed Original Research
2022
Spatial molecular and cellular determinants of STAT3 activation in liver fibrosis progression in non-alcoholic fatty liver disease.
Jiao J, Sanchez JI, Saldarriaga OA, Solis LM, Tweardy DJ, Maru DM, Stevenson HL, Beretta L. Spatial molecular and cellular determinants of STAT3 activation in liver fibrosis progression in non-alcoholic fatty liver disease. JHEP Rep 2022, 5: 100628. PMID: 36687470, DOI: 10.1016/j.jhepr.2022.100628.Peer-Reviewed Original ResearchPost-infantile Giant Cell Hepatitis: A Literature Review and Meta-analysis
Jiao J, Zhang X. Post-infantile Giant Cell Hepatitis: A Literature Review and Meta-analysis. Journal Of Clinical And Translational Pathology 2022, 2: 100-107. PMID: 37092012, PMCID: PMC10117396, DOI: 10.14218/jctp.2022.00016.Peer-Reviewed Original ResearchPost-infantile giant cell hepatitisDisease entityEtiological factorsAdditional etiological factorsGiant cell hepatitisRare disease entityVariable clinical courseGamma-glutamyl transferaseDiffuse distribution patternInterface hepatitisLobular inflammationPortal inflammationUncommon etiologyClinical courseEtiological distributionAutoimmune disordersPoor outcomeHistological featuresWorse outcomesTotal bilirubinMultifactorial etiologyBetter outcomesPatientsViral infectionMeta-Analysis
2021
Gut microbiome features associated with liver fibrosis in Hispanics, a population at high risk for fatty liver disease
Kwan S, Jiao J, Joon A, Wei P, Petty L, Below J, Daniel C, Wu X, Zhang J, Jenq R, Futreal P, Hawk E, McCormick J, Fisher‐Hoch S, Beretta L. Gut microbiome features associated with liver fibrosis in Hispanics, a population at high risk for fatty liver disease. Hepatology 2021, 75: 955-967. PMID: 34633706, PMCID: PMC8930512, DOI: 10.1002/hep.32197.Peer-Reviewed Original ResearchConceptsLiver fibrosisMicrobiome signaturesHigh riskParabacteroides distasonisGut microbiomeCameron County Hispanic CohortEnrichment of PrevotellaGut microbiome signaturesVibration-controlled transient elastographyFatty liver diseaseHigh-risk populationPrevotella abundanceLiver diseaseProinflammatory environmentTransient elastographyPreventive strategiesBacteroides caccaeAlcohol consumptionFibrosisHispanic cohortDisease preventionProtein 2 geneFunctional changesNoninvasive meansB vitaminsLipidomic Profiles of Plasma Exosomes Identify Candidate Biomarkers for Early Detection of Hepatocellular Carcinoma in Patients with Cirrhosis
Sanchez J, Jiao J, Kwan S, Veillon L, Warmoes M, Tan L, Odewole M, Rich N, Wei P, Lorenzi P, Singal A, Beretta L. Lipidomic Profiles of Plasma Exosomes Identify Candidate Biomarkers for Early Detection of Hepatocellular Carcinoma in Patients with Cirrhosis. Cancer Prevention Research 2021, 14: canprevres.0612.2021. PMID: 34253566, PMCID: PMC8546639, DOI: 10.1158/1940-6207.capr-20-0612.Peer-Reviewed Original ResearchConceptsLogistic regression analysisHCC exosomesCirrhotic patientsEarly detectionHepatocellular carcinomaCandidate biomarkersTumor developmentNoninvasive diagnostic biomarkersRegression analysisHCC surveillanceLipid profileEndocannabinoid signalingHCC diagnosisNovel biomarkersLipid classesDiagnostic biomarkersPlasma exosomesLipidomic profilesGlycerophospholipid metabolismHCCPatientsBiomarkersUntargeted lipidomicsCarcinomaDifferential effectsSomatic Mutations in Circulating Cell-Free DNA and Risk for Hepatocellular Carcinoma in Hispanics
Jiao J, Sanchez J, Thompson E, Mao X, McCormick J, Fisher-Hoch S, Futreal P, Zhang J, Beretta L. Somatic Mutations in Circulating Cell-Free DNA and Risk for Hepatocellular Carcinoma in Hispanics. International Journal Of Molecular Sciences 2021, 22: 7411. PMID: 34299031, PMCID: PMC8304329, DOI: 10.3390/ijms22147411.Peer-Reviewed Original ResearchConceptsAdvanced liver fibrosisCell-free DNAHigher cfDNA concentrationsHepatocellular carcinomaLiver fibrosisCfDNA concentrationHCC patientsOverall survivalAdvanced fibrosisHCC risk predictionShorter overall survivalMajor risk factorNon-invasive markerPlasma cell-free DNADetectable mutationsSomatic mutationsCirculating Cell-Free DNARisk factorsHCC developmentCancer-associated genesDeath outcomesFibrosisPatientsNonsynonymous mutationsRisk predictionCirculating Fatty Acids Associated with Advanced Liver Fibrosis and Hepatocellular Carcinoma in South Texas Hispanics
Jiao J, Kwan S, Sabotta C, Tanaka H, Veillon L, Warmoes M, Lorenzi P, Wang Y, Wei P, Hawk E, Almeda J, McCormick J, Fisher-Hoch S, Beretta L. Circulating Fatty Acids Associated with Advanced Liver Fibrosis and Hepatocellular Carcinoma in South Texas Hispanics. Cancer Epidemiology Biomarkers & Prevention 2021, 30: 1643-1651. PMID: 34155064, PMCID: PMC8419070, DOI: 10.1158/1055-9965.epi-21-0183.Peer-Reviewed Original ResearchConceptsAdvanced liver fibrosisNonalcoholic fatty liver diseaseLiver fibrosisHepatocellular carcinomaFree fatty acidsVLC nPlasma concentrationsCameron County Hispanic CohortFatty liver diseaseLiver fibrosis progressionRelatives of patientsStrong predictive factorLow plasma concentrationsSecond-degree relativesLiver fibrosis severityOdd-chain SFAsTexas HispanicsVLC-SFAFIB-4Advanced fibrosisLiver diseaseNAFLD progressionFibrosis progressionN3-PUFAsFatty acidsA Novel Biomarker Panel for the Early Detection and Risk Assessment of Hepatocellular Carcinoma in Patients with Cirrhosis.
Khan IM, Gjuka D, Jiao J, Song X, Wang Y, Wang J, Wei P, El-Serag HB, Marrero JA, Beretta L. A Novel Biomarker Panel for the Early Detection and Risk Assessment of Hepatocellular Carcinoma in Patients with Cirrhosis. Cancer Prev Res (Phila) 2021, 14: 667-674. PMID: 33685927, DOI: 10.1158/1940-6207.CAPR-20-0600.Peer-Reviewed Original ResearchLiver Involvement by Perforated Peptic Ulcer: A Systematic Review
Jiao J, Zhang L. Liver Involvement by Perforated Peptic Ulcer: A Systematic Review. Journal Of Clinical And Translational Pathology 2021, 1: 2-8. PMID: 34927172, PMCID: PMC8681229, DOI: 10.14218/jctp.2021.00007.Peer-Reviewed Original ResearchLiver involvementGastric ulcerDuodenal ulcerPeptic ulcerNon-steroidal anti-inflammatory drugsPerforated Peptic UlcerPerforated duodenal ulcerPeptic ulcer diseaseAnti-inflammatory drugsCareful histologic examinationLiver penetrationGastric remnantLarge ulcersMedian ageFemale patientsMale patientsUlcer diseaseClinicopathological correlationFemale ratioPathological featuresHistologic examinationUlcersPatientsPubMed databaseSystematic review
2020
Bile Acid Changes Associated With Liver Fibrosis and Steatosis in the Mexican‐American Population of South Texas
Kwan S, Jiao J, Qi J, Wang Y, Wei P, McCormick J, Fisher‐Hoch S, Beretta L. Bile Acid Changes Associated With Liver Fibrosis and Steatosis in the Mexican‐American Population of South Texas. Hepatology Communications 2020, 4: 555-568. PMID: 32258950, PMCID: PMC7109342, DOI: 10.1002/hep4.1490.Peer-Reviewed Original ResearchBile acid changesBile acid levelsNonalcoholic fatty liver diseaseFatty liver diseaseBile acid profilesLiver fibrosisLiver diseaseBile acidsAcid levelsHepatocellular carcinomaHigh-risk Mexican-American populationPrimary conjugated bile acidsUnconjugated secondary bile acidsTotal bile acid levelsCameron County Hispanic CohortGut microbiome contributesLithocholic acid levelsSignificant liver fibrosisSecondary bile acidsCommon risk factorsIndividual bile acidsEarly preventive interventionsConjugated bile acidsAcid changesAdvanced fibrosis
2018
Toll-like receptor 4: a target for chemoprevention of hepatocellular carcinoma in obesity and steatohepatitis
Nguyen J, Jiao J, Smoot K, Watt G, Zhao C, Song X, Stevenson H, McCormick J, Fisher-Hoch S, Zhang J, Futreal P, Beretta L. Toll-like receptor 4: a target for chemoprevention of hepatocellular carcinoma in obesity and steatohepatitis. Oncotarget 2018, 9: 29495-29507. PMID: 30034633, PMCID: PMC6047684, DOI: 10.18632/oncotarget.25685.Peer-Reviewed Original ResearchNon-alcoholic fatty liver diseaseTLR4 mRNA expressionHepatocellular carcinomaMRNA expressionIL-6HCC patientsHCC developmentHCC tumorsIL-10 mRNA expressionToll-like receptor 4Fatty liver diseaseWhole-exome sequencingIngenuity Pathway AnalysisDistant liverIL-10Liver diseaseTLR4 inhibitorProinflammatory responseReceptor 4TLR4 activationHCC chemopreventionChemopreventionKey mediatorTumorsMiceTelomerase reverse transcriptase mutations in plasma DNA in patients with hepatocellular carcinoma or cirrhosis: Prevalence and risk factors
Jiao J, Watt G, Stevenson H, Calderone T, Fisher‐Hoch S, Ye Y, Wu X, Vierling J, Beretta L. Telomerase reverse transcriptase mutations in plasma DNA in patients with hepatocellular carcinoma or cirrhosis: Prevalence and risk factors. Hepatology Communications 2018, 2: 718-731. PMID: 29881823, PMCID: PMC5983165, DOI: 10.1002/hep4.1187.Peer-Reviewed Original ResearchEvidence of HCCHepatitis C virusReverse transcriptase mutationsCell-free DNAHepatocellular carcinomaMale patientsTranscriptase mutationsLong-term imaging surveillancePlasma cell-free DNAFrequent genetic alterationsAlcoholic cirrhosisCancer Genome AtlasImaging surveillanceT promoter mutationClinical parametersMale sexPoor prognosisC virusRisk factorsSimilar prevalenceEarly biomarkersFamily historyHigh prevalenceCirrhosisPatients